Loading...

Eve Rodler

Title(s)Associate Adjunct Professor, Hematology and Oncology
SchoolUniversity of California, Davis
Phone916-734-3772
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Symonds L, Linden H, Gadi V, Korde L, Rodler E, Gralow J, Redman M, Baker K, Wu QV, Jenkins I, Kurland B, Garrison M, Smith J, Anderson J, Van Haelst C, Specht J. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. Clin Breast Cancer. 2019 04; 19(2):e283-e296. PMID: 30737173.
      View in: PubMed
    2. Jones RL, Katz D, Loggers ET, Davidson D, Rodler ET, Pollack SM. Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. Med Oncol. 2017 Aug 29; 34(10):167. PMID: 28852958.
      View in: PubMed
    3. Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res. 2016 06 15; 22(12):2855-64. PMID: 26801247.
      View in: PubMed
    4. Burt A, Berriochoa J, Korpak A, Rodler E, Jones RL, Weisstein J, Patel S. Treatment of chest wall sarcomas: a single-institution experience over 20 years. Am J Clin Oncol. 2015 Feb; 38(1):80-6. PMID: 23563212.
      View in: PubMed
    5. Chang AE, Chai X, Pollack SM, Loggers E, Rodler E, Dillon J, Parvathaneni U, Moe KS, Futran N, Jones RL. Analysis of clinical prognostic factors for adult patients with head and neck sarcomas. Otolaryngol Head Neck Surg. 2014 Dec; 151(6):976-83. PMID: 25257906.
      View in: PubMed
    6. Bremjit PJ, Jones RL, Chai X, Kane G, Rodler ET, Loggers ET, Pollack SM, Pillarisetty VG, Mann GN. A contemporary large single-institution evaluation of resected retroperitoneal sarcoma. Ann Surg Oncol. 2014 Jul; 21(7):2150-8. PMID: 24615180.
      View in: PubMed
    7. Meyer JM, Perlewitz KS, Hayden JB, Doung YC, Hung AY, Vetto JT, Pommier RF, Mansoor A, Beckett BR, Tudorica A, Mori M, Holtorf ML, Afzal A, Woodward WJ, Rodler ET, Jones RL, Huang W, Ryan CW. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013 Dec 15; 19(24):6902-11. PMID: 24132922.
      View in: PubMed
    8. Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL. Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol. 2013 Jun; 30(2):501. PMID: 23456619.
      View in: PubMed
    9. Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther. 2013 Feb; 13(2):211-23. PMID: 23406562.
      View in: PubMed
    10. Ferreira BP, Rodler ET, Loggers ET, Pollack SM, Jones RL. Systemic therapy in primary angiosarcoma of the spleen. Rare Tumors. 2012 Oct 10; 4(4):e55. PMID: 23372919.
      View in: PubMed
    11. Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM. Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Res. 2012 Jun 25; 2(1):34. PMID: 22731662.
      View in: PubMed
    12. Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012; 7(2):e32165. PMID: 22384167.
      View in: PubMed
    13. Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012 Sep 15; 118(18):4564-70. PMID: 22359263.
      View in: PubMed
    14. Eary JF, Hawkins DS, Rodler ET, Conrad EU. (18)F-FDG PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging. 2011; 1(1):47-53. PMID: 23133794.
      View in: PubMed
    15. Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL. Immune-based therapies for sarcoma. Sarcoma. 2011; 2011:438940. PMID: 21331153.
      View in: PubMed
    16. Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. NCCN Clinical Practice Guidelines Cancer-related fatigue. J Natl Compr Canc Netw. 2010 Aug; 8(8):904-31. PMID: 20870636.
      View in: PubMed
    17. Rodler E, Korde L, Gralow J. Current treatment options in triple negative breast cancer. Breast Dis. 2010; 32(1-2):99-122. PMID: 21778572.
      View in: PubMed
    18. Rodler E, Welborn J, Hatcher S, Unger K, Larkin E, Gumerlock PH, Wun T, Richman C. Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature. Am J Hematol. 2004 Apr; 75(4):231-8. PMID: 15054816.
      View in: PubMed